Pfizer’s PROTAC treatment for breast cancer has shown no significant improvement over oral SERDs (Selective Estrogen Receptor Downregulators) according to the latest clinical results. The company had invested $1 billion upfront to license Arvinas’ targeted protein degrader. Despite this substantial investment, the new data suggests that the drug does not offer a substantial advantage over existing treatments for breast cancer.
Source: https://endpts.com/asco25-arvinas-pfizers-protac-in-breast-cancer-no-better-than-oral-serds